Irinotecan Uses, Dosage, Side Effects and Interactions
Camptosar
Camptosar was the first irinotecan product the FDA approved, in June 1996. An FDA-approved generic with the same active ingredient is listed.
Irinotecan is an intravenous chemotherapy (a topoisomerase inhibitor) used for metastatic colon or rectum cancer, and, as the liposomal product Onivyde, for metastatic pancreatic cancer.
Quick links
Ask Anything About IrinotecanType a question in your own words. Answered from its FDA label in seconds.Every other section of this page is in the dots on the left edge of your screen: point at one to see where it goes.Every other section of this page is one tap away: use the arrow tab on the left edge of your screen.
Irinotecan in Short
- Drug class Topoisomerase Inhibitor How the FDA classifies it
What it treatsIrinotecan hydrochloride injection (including Camptosar) treats metastatic carcinoma of the colon or rectum (cancer that has spread). It is used first, together with 5-fluorouracil (5-FU) and leucovorin. It is also used when the cancer has come back or worsened after earlier fluorouracil-based treatment.
- How you get it Prescription only
- Comes asInjection (into a vein)
- The FDA’s strongest warningBoxed warning The FDA’s most serious alert. Read what it says
- Generic versionYes, FDA-approved Listed with the FDA, which does not mean every pharmacy stocks it
The Pharmacist’s Take
Irinotecan (Camptosar) is an IV chemotherapy that blocks topoisomerase I, an enzyme cancer cells need to copy their DNA, and since the mid-1990s it has been a standard partner to 5-FU and leucovorin for colon or rectal cancer that has spread (FDA-approved generics are listed), while a separate fat-coated (liposomal) form, Onivyde, treats pancreatic cancer that has spread. It is a demanding treatment, and diarrhea, nausea, tiredness and hair loss are what most people notice. The boxed warning is for severe diarrhea and dangerously low white blood cells, so report fever or any diarrhea to your care team right away.
Key Takeaways From the HelloPharmacist Team
- Expect a 90-minute IV infusion at the clinic, given weekly, every two weeks or every three weeks depending on your regimen.
- Keep loperamide at home and use it exactly as your care team directs for diarrhea starting a day or more after treatment.
- Tell the nurse at once if sweating, cramping, watery eyes, drooling or a slow heartbeat start during or soon after the infusion.
- Keep every lab appointment, because your blood counts are checked regularly and doses are held if white cells drop too low.
FDA Boxed WarningThe FDA’s strongest safety alert. Read what it says about Irinotecan.
Onivyde can cause severe, life-threatening low white blood cell counts and severe diarrhea.
Neutropenia (low infection-fighting white cells) has led to fatal infections and fevers. Your blood counts are checked regularly, and treatment is held if counts drop too low or a neutropenic fever develops. Severe diarrhea can also occur. Treatment is held for moderate to severe diarrhea, and Onivyde must not be given if you have a bowel obstruction. Loperamide is used for late diarrhea and atropine, if safe for you, for early diarrhea. Report fever or any diarrhea right away.
Patient Information Guide for Irinotecan
What It’s Used For
Irinotecan is a chemotherapy given into a vein for certain advanced cancers.
- Irinotecan hydrochloride injection (including Camptosar): first-line treatment of metastatic colon or rectum cancer with 5-FU and leucovorin.
- Irinotecan hydrochloride injection (including Camptosar): metastatic colon or rectum cancer that has returned or progressed after fluorouracil-based therapy.
- Onivyde: first-line metastatic pancreatic adenocarcinoma in adults, with oxaliplatin, fluorouracil and leucovorin.
- Onivyde: metastatic pancreatic adenocarcinoma after progression on gemcitabine-based therapy, with fluorouracil and leucovorin. It is not approved as a single agent.
How It Works
Irinotecan is a camptothecin that targets topoisomerase I, an enzyme that relieves tension in DNA as cells copy it. Irinotecan and its active form, SN-38, trap the enzyme on the DNA so the breaks cannot be sealed.
This causes double-strand DNA damage while cells are dividing. Cells cannot repair that damage efficiently, so they die.
Drug Class
Drug Class
- Topoisomerase Inhibitor
Detailed classifications and sources
The FDA sorts a drug’s active ingredient by how it works, what it does in the body and its chemical structure, and gives it one main drug class.
Drug Class
Established Pharmacologic Class (EPC)- Topoisomerase Inhibitor
The main drug class the FDA gives it. It is the class named on the drug’s label.
How It Works
Mechanism of action (MoA)- Topoisomerase Inhibitors
What it does at the smallest level, such as a receptor or enzyme it blocks or switches on.
What It Does in the Body
Physiologic effect (PE)None listed for Irinotecan in the FDA’s index.
From our Patient Information GuideIrinotecan is a camptothecin that targets topoisomerase I, an enzyme that relieves tension in DNA as cells copy it. Irinotecan and its active form, SN-38, trap the enzyme on the DNA so the breaks cannot be sealed. Read How Irinotecan Works
A change it makes in how the body works.
Chemical Family
Chemical structure (CS)None listed for Irinotecan in the FDA’s index.
The chemical family it belongs to, by its structure.
Drug Family
WHO ATC classification- Topoisomerase 1 (TOP1) inhibitors
How the World Health Organization groups it: by the part of the body it acts on and what it treats.
The classes are the FDA’s own words, from its index of drug labels, published in the National Library of Medicine’s RxClass. The description under What It Does in the Body is written by the HelloPharmacist team, not the FDA. Read the FDA’s definitions. The drug family is the World Health Organization’s ATC classification. Reference only, not medical advice.
Dosage
Irinotecan is given only by IV infusion in a clinic or hospital, generally over about 90 minutes. Schedules vary by product and regimen, and may be weekly, every two weeks or every three weeks.
- Camptosar and other irinotecan injections are given before leucovorin and 5-FU in combination regimens.
- Onivyde is given before oxaliplatin, fluorouracil and leucovorin, after premedication with a corticosteroid and anti-nausea drug.
- Onivyde cannot be swapped for other irinotecan products.
Follow your prescriber's plan and contact them if you miss a visit.
Typical Doses
Your prescriber chooses your dose, so take it exactly as prescribed.
Irinotecan Injection
Colon or rectal cancer that has spread
Adults getting irinotecan with 5-FU and leucovorin, regimen 1 Usual dose 125 mg/m2 on days 1, 8, 15, 22 of a 6-week cycle
- 125 mg/m2 intravenous infusion over 90 minutes, days 1, 8, 15, 22, with LV 20 mg/m2 intravenous bolus and 5-FU 500 mg/m2 intravenous bolus on days 1, 8, 15, 22
- Next cycle begins on day 43
Good to know
Dose Level -1 is 125 to 100 mg/m2 (LV 20, 5-FU 400); Dose Level -2 is 75 mg/m2 (LV 20, 5-FU 300)
Adults getting irinotecan with 5-FU and leucovorin, regimen 2 Usual dose 180 mg/m2 on days 1, 15, 29 of a 6-week cycle
- 180 mg/m2 intravenous infusion over 90 minutes, days 1, 15, 29, with LV 200 mg/m2 intravenous infusion over 2 hours, 5-FU 400 mg/m2 intravenous bolus and 5-FU 600 mg/m2 intravenous infusion over 22 hours on days 1, 2, 15, 16, 29, 30
- Next cycle begins on day 43
Good to know
Dose Level -1 is 150 mg/m2 (LV 200, 5-FU 400 bolus changed to 320, infusion 480); Dose Level -2 is 120 mg/m2 (LV 200, 5-FU 240 bolus, 360 infusion)
Adults getting irinotecan alone, weekly Usual dose 125 mg/m2 on days 1, 8, 15, 22 Highest dose 150 mg/m2
- 125 mg/m2 intravenous infusion over 90 minutes, days 1, 8, 15, 22 then 2-week rest
Good to know
Dose Level -1 is 100 mg/m2; Dose Level -2 is 75 mg/m2
Adults getting irinotecan alone, every 3 weeks Usual dose 350 mg/m2 once every 3 weeks
- 350 mg/m2 intravenous infusion over 90 minutes, once every 3 weeks
Good to know
Dose Level -1 is 300 mg/m2; Dose Level -2 is 250 mg/m2; may be adjusted as low as 200 mg/m2
Onivyde
Pancreatic cancer that has spread
Metastatic pancreatic adenocarcinoma, first-line, with oxaliplatin, fluorouracil and leucovorin Usual dose 50 mg/m2 every 2 weeks
- 50 mg/m2 intravenous infusion over 90 minutes every 2 weeks, regardless of UGT1A1*28 genotype
Good to know
No recommended dose for serum bilirubin above the upper limit of normal; after adverse reactions resume at 40 mg/m2 (first), 32.5 mg/m2 (second), 25 mg/m2 (third); discontinue at fourth
Metastatic pancreatic adenocarcinoma after gemcitabine-based therapy, with fluorouracil and leucovorin Usual dose 70 mg/m2 every 2 weeks
- 70 mg/m2 intravenous infusion over 90 minutes every 2 weeks
Good to know
After Grade 3 or 4 reactions resume at 50 mg/m2 (first), 43 mg/m2 (second); discontinue at third. No recommended dose for bilirubin above upper limit of normal
Adults known to be homozygous for UGT1A1*28 Starting dose 50 mg/m2 over 90 minutes Usual dose 70 mg/m2 every 2 weeks
Step by step
- Starting dose 50 mg/m2 intravenous infusion over 90 minutes
- Increase to 70 mg/m2 as tolerated in subsequent cycles
Good to know
After Grade 3 or 4 reactions without previous increase to 70 mg/m2 resume at 43 mg/m2 (first), 35 mg/m2 (second); discontinue at third
Side Effects
Common side effects seen in studies include:
Common side effects
- Diarrhea
- Nausea and vomiting
- Abdominal pain or cramping
- Low white blood cell counts (neutropenia)
- Anemia (low red blood cells)
- Weakness or tiredness
- Loss of appetite and weight loss
- Hair loss
- Constipation
- Low white blood cells, red blood cells or platelets
When to get medical help
- Severe diarrhea, especially later diarrhea starting more than 24 hours after treatment, which can cause dehydration or infection
- Fever or signs of infection, which can signal dangerously low white blood cells
- Signs of a serious allergic reaction such as swelling, trouble breathing or a severe rash
- New or worsening shortness of breath, cough or fever, which may signal lung problems
- Severe vomiting or diarrhea with dehydration, since kidney problems can follow
- Early symptoms during or soon after infusion such as sweating, flushing, drooling, watery eyes, cramping or a slow heartbeat
Warnings and Precautions
- Severe diarrhea: early (during or soon after infusion) and late (after 24 hours). Late diarrhea can cause dehydration and infection. Begin loperamide at the first loose stool as directed.
- Low white blood cells: can lead to serious or fatal infections. Higher risk with the UGT1A1*28 variant, elevated bilirubin, or past pelvic or abdominal radiation.
- Allergic reactions: severe reactions can occur and treatment is stopped.
- Lung problems: new cough, shortness of breath or fever need prompt evaluation.
- Kidney problems: usually after dehydration from vomiting or diarrhea.
- Pregnancy: can harm a baby.
Interactions
Some medicines change irinotecan levels in the body.
- Strong CYP3A4 inducers (phenytoin, phenobarbital, carbamazepine, St. John's wort, rifampin, rifabutin): lower irinotecan exposure.
- Strong CYP3A4 inhibitors (ketoconazole, clarithromycin, itraconazole, voriconazole, ritonavir): raise exposure and risk.
- UGT1A1 inhibitors (atazanavir, gemfibrozil, indinavir): may raise SN-38 levels.
- Diuretics and laxatives: avoid during diarrhea.
Interactions Listed in the FDA-Approved Label
From the Irinotecan prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
-
Strong CYP3A4 inducers (phenytoin, phenobarbital, carbamazepine, St. John's wort, rifampin, rifabutin)What happensExposure to irinotecan or its active metabolite SN-38 is substantially reduced.What to doDo not administer unless there are no therapeutic alternatives; consider substituting non-enzyme inducing therapies at least 2 weeks before starting irinotecan.
-
Strong CYP3A4 or UGT1A1 inhibitors (ketoconazole, clarithromycin, indinavir, itraconazole, lopinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telaprevir, voriconazole, atazanavir, gemfibrozil)What happensMay increase systemic exposure to irinotecan or SN-38.What to doDiscontinue strong CYP3A4 inhibitors at least 1 week before starting irinotecan; do not administer unless there are no therapeutic alternatives.
-
What happensIrinotecan disposition was not substantially altered; SN-38 Cmax and AUC0-24 were reduced by 14% and 8% when irinotecan was followed by 5-FU and LV.What to doThis sequence of administration was used in the combination trials and is recommended.
Read the label’s full interactions text
7 DRUG INTERACTIONS • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with irinotecan hydrochloride injection. • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with irinotecan hydrochloride injection. 7.1 5-Fluorouracil (5-FU) and Leucovorin (LV) In a phase 1 clinical study involving irinotecan, 5-fluorouracil (5-FU), and leucovorin (LV) in 26 patients with solid tumors, the disposition of irinotecan was not substantially altered when the drugs were co-administered. Although the C max and AUC 0-24 of SN-38,the active metabolite, were reduced (by 14% and 8%, respectively) when irinotecan was followed by 5-FU and LV administration compared with when irinotecan was given alone, this sequence of administration was used in the combination trials and is recommended. Formal in vivo or in vitro drug interaction studies to evaluate the influence of irinotecan on the disposition of 5-FU and LV have not been conducted. 7.2 Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. John's wort. The appropriate starting dose for patients taking these or other strong inducers such as rifampin and rifabutin has not been defined. Consider substituting non-enzyme inducing therapies at least 2 weeks prior to initiation of irinotecan hydrochloride injection therapy. Do not administer strong CYP3A4 inducers with irinotecan hydrochloride injection unless there are no therapeutic alternatives. 7.3 Strong CYP3A4 or UGT1A1 Inhibitors Irinotecan and its active metabolite, SN-38, are metabolized via the human cytochrome P450 3A4 isoenzyme (CYP3A4) and uridine diphosphate-glucuronosyl transferase 1A1 (UGT1A1), respectively,.
Excerpted: the section continues on the label. Read the full Drug Interactions section on DailyMed →
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before You Start
- Do not use after a severe allergic reaction to irinotecan or Onivyde.
- Do not use Onivyde with a bowel obstruction. Irinotecan treatment should wait until an obstruction resolves.
- Pregnancy: use effective contraception during treatment and for 6 months after. Males should use condoms for 3 months after.
- Do not breastfeed during treatment and for 7 days after.
- Effectiveness in children has not been established.
- Adults over 65 are monitored closely for diarrhea.
- Use caution with kidney or liver impairment. It is not recommended on dialysis.
- Tell your doctor about Gilbert's syndrome, lung disease, or past radiation to the pelvis or abdomen.
Overdose
Overdoses of about twice the recommended dose have been reported and may be fatal. The main effects are severe neutropenia and severe diarrhea. There is no known antidote, so care focuses on supportive treatment to prevent dehydration and treat infections.
Half-Life and How Your Body Processes It
After IV infusion, irinotecan levels fall with a half-life of about 6 to 12 hours, and SN-38 about 10 to 20 hours. The liver converts irinotecan to SN-38, then the UGT1A1 enzyme inactivates SN-38. People with reduced UGT1A1 activity have higher SN-38 levels. CYP3A4 also breaks down irinotecan. Part of the drug leaves in urine and bile.
Storage
Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° and 30°C (59° and 86°F). Protect from freezing. Protect from light.
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI
Irinotecan: Pharmacist Answers to Common Questions
Quick, plain-English answers to the questions patients ask most about Irinotecan — the kind of thing our pharmacy team would talk through with you at the counter.
What is irinotecan used for?
How is irinotecan given?
What should I do if I get diarrhea on irinotecan?
What happens if I miss a dose of irinotecan?
Can I take other medicines or herbal products with irinotecan?
Is irinotecan safe during pregnancy or breastfeeding?
Is irinotecan available over the counter?
When was irinotecan first available?
Who makes irinotecan?
What is the brand name of irinotecan?
What is the generic name of Camptosar?
What drug class is irinotecan?
Is there a generic version of irinotecan?
What strengths does irinotecan come in?
Is there a irinotecan shortage?
Where can I read the irinotecan prescribing information (package insert)?
Is irinotecan gluten free?
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI
Ask Anything About Irinotecan
Skip the scrolling. Ask in your own words and get an answer from Irinotecan’s FDA label and our pharmacists’ own work.
Name another drug or a supplement in your question and we check both.
AI answers from FDA labels and our own records, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.How this works
- Sources: Irinotecan’s FDA label, including the clinical studies it reports, and the label of any drug you name; our pharmacists’ own work, such as our Do Not Crush list and our published answers to readers’ questions; our pharmacy prices and the Natural Medicines supplement database.
- Written by AI: Answers are written by AI from those sources, and AI can make mistakes. Check what you read here with your doctor or pharmacist before you act on it.
- Reviewed afterward: Our pharmacy team reviews every question and answer afterward to check it for accuracy, and when we find an error, we correct how the box answers. Read more in How we use AI.
- Not medical advice. In an emergency, call 911, Poison Control at 1-800-222-1222, or 988.
More About Irinotecan on HelloPharmacist
Still have a question? A licensed pharmacist answers for free, usually within a day.Irinotecan Forms and Strengths (How It Comes)
Irinotecan comes in 1 dose form, the injection. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Irinotecan inactive ingredients by manufacturer.
Injection
How this form is used
- Camptosar is used for metastatic colon or rectum cancer, first-line with 5-FU and leucovorin or after earlier fluorouracil-based therapy
- Onivyde is used with other drugs for metastatic pancreatic adenocarcinoma, and is not for use alone
- Irinotecan hydrochloride injection is used for metastatic colon or rectum cancer
- Camptosar is given as a 90-minute IV infusion, followed by leucovorin and 5-FU when used in combination
- Onivyde is given as a 90-minute IV infusion, before oxaliplatin, fluorouracil and leucovorin
- Onivyde must not be substituted for other irinotecan products
- Onivyde is given after a corticosteroid and an anti-nausea medicine about 30 minutes beforehand
Irinotecan on the U.S. Market: Products, Makers and Brands
How Irinotecan appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
13 companies list 28 Irinotecan product records with the FDA, mostly as injection; the earliest marketing or approval year on record is 1996. The one brand name in the directory today is Camptosar; the rest are generics.
Also listed with the FDA, not a patient dose form: Powder (11) · Unfinished powder, for suspension (1) — bulk drug substance and unfinished product sold to compounders and other manufacturers to finish, and multi-item kits. These aren’t counted in the dose-form total above.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
How Widely Irinotecan Is Used (Medicaid Data)
How many Irinotecan prescriptions Medicaid paid for in Q1–Q4 2025, every brand, strength and form together. Medicaid is one program, so total U.S. use is higher.
How commonly is Irinotecan prescribed? Of the 1,666 medications we measure, Irinotecan ranks #780 by Medicaid prescriptions — more than 53% of them.
Utilization by Irinotecan product
Pick a strength and form to see its own numbers. Brand and generic versions are counted together.
5 ML irinotecan hydrochloride 20 MG/ML Injection Most dispensed
13 of 24 listed NDCs had Medicaid claims. RxNorm 1726324
2 ML irinotecan hydrochloride 20 MG/ML Injection
13 of 24 listed NDCs had Medicaid claims. RxNorm 1726319
10 ML irinotecan hydrochloride liposome 4.3 MG/ML Injection
1 of 1 listed NDCs had Medicaid claims. RxNorm 1719772
25 ML irinotecan hydrochloride 20 MG/ML Injection
1 of 1 listed NDCs had Medicaid claims. RxNorm 1726492
15 ML irinotecan hydrochloride 20 MG/ML Injection
3 of 6 listed NDCs had Medicaid claims. RxNorm 1726333
Dollars are what Medicaid paid before the rebates drug makers send back, so its real cost is lower.
Source: Medicaid State Drug Utilization Data (CMS), all states. 31 of the 56 listed Irinotecan NDCs had Medicaid claims.
Compare Irinotecan Products
A representative set of FDA-listed product records for Irinotecan — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Injection | ||||
| 20 mg/mL | Intravenous | Actavis Pharma, Inc. | ANDA | View NDC → |
| 20 mg/mL | Intravenous | Apotex Corp. × 2 listings | ANDA | View NDC → |
| 20 mg/mL | Intravenous | BluePoint Laboratories | ANDA | View NDC → |
| 40 mg/2 mL | Intravenous | BluePoint Laboratories | ANDA | View NDC → |
| 100 mg/5 mL | Intravenous | BluePoint Laboratories | ANDA | View NDC → |
| 20 mg/mL | Intravenous | Eugia US LLC × 4 listings | ANDA | View NDC → |
| 20 mg/mL | Intravenous | Fresenius Kabi USA, LLC | ANDA | View NDC → |
| 20 mg/mL | Intravenous | Gland Pharma Limited × 2 listings | ANDA | View NDC → |
| 20 mg/mL | Intravenous | Hikma Pharmaceuticals USA Inc. × 3 listings | ANDA | View NDC → |
| 20 mg/mL | Intravenous | Hospira, Inc. | ANDA | View NDC → |
| 4.3 mg/mL | Intravenous | Ipsen Biopharmaceuticals, Inc. | NDA | View NDC → |
| 20 mg/mL | Intravenous | Northstar Rx LLC × 2 listings | ANDA | View NDC → |
| 20 mg/mL | Intravenous | Pharmacia & Upjohn Company LLC × 3 listings | NDA | View NDC → |
| 20 mg/mL | Intravenous | Qilu Pharmaceutical Co., Ltd. × 3 listings | ANDA | View NDC → |
| 20 mg/mL | Intravenous | Xiromed LLC × 2 listings | ANDA | View NDC → |
Showing 28 of 28 products — FDA National Drug Code Directory. See every product, package size and price: browse all 28 Irinotecan NDCs →
Irinotecan Side Effects Reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Irinotecan — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Irinotecan in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Irinotecan FDA Approval History
How Irinotecan went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Irinotecan Recall History
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no Irinotecan recalls since July 2021.
✅No Irinotecan recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Nov 19, 2026.
Irinotecan in RxNorm: From Ingredient to Every Form and Strength
RxNorm is the U.S. National Library of Medicine’s standard name for every version of a medicine, the code pharmacy and prescribing systems share. This page starts from one ingredient (IN); each dose form (SCDF) branches from it, and each exact strength (SCD) from its form. Combination products are separate concepts with their own pages.
- Dose forms
- 1
- Strengths
- 5
- Forms in current FDA listings
- 1 of 1
RxCUI 51499 -
Dose form (SCDF) InjectionIn current FDA listings
RxCUI 1726318Its 5 strengths (SCD)-
2 mL irinotecan hydrochloride 20 mg/mL
RxCUI 1726319 -
5 mL irinotecan hydrochloride 20 mg/mL
RxCUI 1726324 -
10 mL irinotecan hydrochloride liposome 4.3 mg/mL
RxCUI 1719772 -
15 mL irinotecan hydrochloride 20 mg/mL
RxCUI 1726333 -
25 mL irinotecan hydrochloride 20 mg/mL
RxCUI 1726492
-
2 mL irinotecan hydrochloride 20 mg/mL
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Irinotecan Supply and Shortage Status
Whether Irinotecan is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
Irinotecan Brand Names
Irinotecan has one brand name on record: Camptosar. A brand name is one company's name for the medicine; a generic has the same active ingredient under its generic name.
Who Makes Irinotecan: Manufacturers and Labelers
13 companies list Irinotecan products with the FDA. By number of product records, the largest are Eugia US LLC, BluePoint Laboratories, Hikma Pharmaceuticals USA Inc.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Sources for This Irinotecan Page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Ipsen Biopharmaceuticals, Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →